Health and Fitness Health and Fitness
Thu, October 27, 2011
Wed, October 26, 2011
Tue, October 25, 2011
Mon, October 24, 2011
[ Mon, Oct 24th 2011 ] - Market Wire
Cigna to Acquire HealthSpring
Sat, October 22, 2011
Fri, October 21, 2011
Thu, October 20, 2011
Wed, October 19, 2011
Tue, October 18, 2011
Mon, October 17, 2011
Sun, October 16, 2011
Sat, October 15, 2011
Fri, October 14, 2011
Thu, October 13, 2011

Law Offices of Howard G. Smith Announces Class Action Lawsuit Against K-V Pharmaceutical Company


//health-fitness.news-articles.net/content/2011/ .. -lawsuit-against-k-v-pharmaceutical-company.html
Published in Health and Fitness on Thursday, October 20th 2011 at 18:01 GMT by Market Wire   Print publication without navigation


BENSALEM, Pa.--([ BUSINESS WIRE ])--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of purchasers of the common stock of K-V Pharmaceutical Company (aK-V Pharmaceuticala or the aCompanya) (NYSE:KV-A) (NYSE:KV-B) between February 14, 2011 and April 4, 2011, inclusive (the aClass Perioda), seeking to pursue remedies under the Securities Exchange Act of 1934. The class action lawsuit was filed in the United States District Court for the Eastern District of Missouri.

KV Pharmaceutical is a specialty pharmaceutical company engaged in the acquisition, development, manufacture and marketing of branded and generic/non-branded prescription pharmaceutical products in the United States, primarily focusing on womena™s healthcare. The Complaint alleges that during the Class Period defendants issued false and/or misleading statements concerning the Companya™s business and financial prospects. Specifically, the Complaint alleges that defendants misrepresented that the Food and Drug Administration (FDA) had granted K-V Pharmaceutical the exclusive distribution rights over "Makena," a drug used to prevent miscarriages, and that the FDA would enforce those rights by preventing K-Va™s competitors from distributing generic formulations of the drug. The Complaint further alleges that defendants failed to disclosed that the druga™s $1,500 price actually would reduce the availability of Makena to low-income and other at-risk groups.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased K-V Pharmaceutical common stock between February 14, 2011 and April 4, 2011, you have certain rights, and have 60 days from October 19, 2011, to move for lead plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at 215-638-4847, Toll Free at 888-638-4847, or by email to [ howardsmith@howardsmithlaw.com ], or visit our website at [ http://www.howardsmithlaw.com ].


Publication Contributing Sources